Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (12): 1105-1109.doi: 10.35541/cjd.20210744
• Expert Commentary • Previous Articles Next Articles
Zhao Zuotao#br# #br#
Received:
2021-10-12
Revised:
2021-11-17
Online:
2021-12-15
Published:
2021-12-01
Contact:
Zhao Zuotao
E-mail:zhaozuotaotao@163.com
Supported by:
Zhao Zuotao. Diagnosis and treatment of chronic urticaria: current status and future prospects[J]. Chinese Journal of Dermatology, 2021, 54(12): 1105-1109.doi:10.35541/cjd.20210744
[1] | Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria[J]. Allergy, 2018,73(7):1393⁃1414. doi: 10.1111/all.13397. |
[2] | 中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南(2018版)[J]. 中华皮肤科杂志, 2019,52(1):1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001. |
[3] | 于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷(CU⁃Q2oL)信效度验证[J]. 中华皮肤科杂志, 2020,53(12):992⁃997. doi: 10.35541/cjd.20200091. |
[4] | Dong W, An J, Geng P, et al. Years lost due to disability from skin diseases in China 1990⁃2017: findings from the Global Burden of Disease Study 2017[J]. Br J Dermatol, 2020,182(1):248⁃250. doi: 10.1111/bjd.18329. |
[5] | Jiao Q, Luo Y, Scheffel J, et al. Skin mast cells contribute to Sporothrix schenckii infection[J]. Front Immunol, 2020,11:469. doi: 10.3389/fimmu.2020.00469. |
[6] | Yu M, Song XT, Liu B, et al. The emerging role of mast cells in response to fungal infection[J]. Front Immunol, 2021,12:688659. doi: 10.3389/fimmu.2021.688659. |
[7] | Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know[J]. J Allergy Clin Immunol, 2017,139(6):1772⁃1781.e1. doi: 10.1016/j.jaci.2016.08.050. |
[8] | 陈玉迪, 耿鹏, 赵嘉惠, 等. 慢性自发性荨麻疹:奥马珠单抗治疗作用机制与疗效评估[J]. 中华皮肤科杂志, 2019,52(9):652⁃655. doi: 10.3760/cma.j.issn.0412⁃4030.2019.09.014. |
[9] | 陈玉迪, 刘擘, 宋晓婷, 等. 临界温度阈值检测在冷接触性荨麻疹中的临床应用[J]. 中华皮肤科杂志, 2020,53(5):352⁃355. doi: 10.35541/cjd.20190840. |
[10] | Zhao Z, Reimann S, Wang S, et al. Ordinary vibratory angioedema is not generally associated with ADGRE2 mutation[J]. J Allergy Clin Immunol, 2019,143(3):1246⁃1248.e4. doi: 10.1016/j.jaci.2018.10.049. |
[11] | 宋晓婷, 刘擘, 陈玉迪, 等. 奥马珠单抗治疗27例人工荨麻疹回顾分析[J]. 中华皮肤科杂志, 2021,54(12):1092⁃1096. doi: 10.35541/cjd.20210473. |
[12] | 赵作涛. 诱导性荨麻疹治疗的选择[J]. 皮肤病与性病, 2015,37(1):19. |
[13] | Chen YD, Maurer M, Yu M, et al. Addition of omalizumab to antihistamine treatment in chronic urticaria: a real⁃world study in China[J]. Ann Allergy Asthma Immunol, 2020,125(2):217⁃219. doi: 10.1016/j.anai.2020.04.026. |
[14] | Chen Y, Yu M, Huang X, et al. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both[J]. World Allergy Organ J, 2021,14(1):100501. doi: 10.1016/j.waojou.2020.100501. |
[15] | Song XT, Chen YD, Yu M, et al. Omalizumab in children and adolescents with chronic urticaria: a 16⁃week real⁃world study[J]. Allergy, 2021,76(4):1271⁃1273. doi: 10.1111/all.14686. |
[16] | Yu M, Terhorst⁃Molawi D, Altrichter S, et al. Omalizumab in chronic inducible urticaria: a real⁃life study of efficacy, safety, predictors of treatment outcome and time to response[J]. Clin Exp Allergy, 2021,51(5):730⁃734. doi: 10.1111/cea.13838. |
[17] | 宋晓婷, 刘擘, 陈玉迪, 等. 奥马珠单抗治疗慢性自发性荨麻疹的疗效及安全性分析[J]. 中华皮肤科杂志, 2021,54(12):1063⁃1070. doi: 10.35541/cjd.20210324. |
[18] | 于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷(CU⁃Q2oL)信效度验证[J]. 中华皮肤科杂志, 2020,53(12):992⁃997. doi: 10.35541/cjd.20200091. |
[19] | 于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证[J]. 中华皮肤科杂志, 2020,53(7):533⁃538. doi: 10. 35541/cjd.20191190. |
[20] | 于淼, 陈玉迪, 刘擘, 等. 慢性自发性荨麻疹的临床评估体系[J]. 中华皮肤科杂志, 2021,53(12):1117⁃1121. doi: 10.35541/cjd.20210379. |
[21] | Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria[J/OL]. Allergy,2021(2021⁃09⁃18). doi: 10.1111/all. 15090.[published online ahead of print] |
[22] | 陈玉迪, 耿鹏, 涂平, 等. 抗组胺药物在变态反应性疾病中的应用[J]. 临床药物治疗杂志, 2019,17(1):23⁃26. doi: 10.3969/j.issn.1672⁃3384.2019.01.006. |
[23] | Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta⁃analysis of randomized clinical trials[J]. J Allergy Clin Immunol, 2016,137(6):1742⁃1750.e4. doi: 10.1016/j.jaci.2015.12.1342. |
[24] | Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria[J]. N Engl J Med, 2013,368(10):924⁃935. doi: 10.1056/NEJMoa121 5372. |
[25] | Ertas R, Ozyurt K, Atasoy M, et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change[J]. Allergy, 2018,73(3):705⁃712. doi: 10.1111/all.13345. |
[26] | Sussman G, Hébert J, Gulliver W, et al. Omalizumab re⁃treatment and step⁃up in patients with chronic spontaneous urticaria: OPTIMA trial[J]. J Allergy Clin Immunol Pract, 2020,8(7):2372⁃2378.e5. doi: 10.1016/j.jaip.2020.03.022. |
[27] | Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab[J]. J Allergy Clin Immunol, 2008,122(3):569⁃573. doi: 10.1016/j.jaci.2008.07.006. |
[28] | Maurer M, Eyerich K, Eyerich S, et al. Urticaria: Collegium Internationale Allergologicum (CIA) update 2020[J]. Int Arch Allergy Immunol, 2020,181(5):321⁃333. doi: 10.1159/000507218. |
[29] | Tontini C, Marinangeli L, Cognigni M, et al. Omalizumab in chronic spontaneous urticaria: patient⁃tailored tapering or planned discontinuation?[J]. Ann Allergy Asthma Immunol, 2015,115(2):147⁃148. doi: 10.1016/j.anai.2015.05.005. |
[30] | Türk M, Maurer M, Yılmaz İ. How to discontinue omalizumab in chronic spontaneous urticaria?[J]. Allergy, 2019,74(4):821⁃824. doi: 10.1111/all.13675. |
[31] | Türk M, Carneiro⁃Leão L, Kolkhir P, et al. How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers[J]. J Allergy Clin Immunol Pract, 2020,8(1):113⁃124. doi: 10.1016/j.jaip.2019.07.021. |
[32] | Staubach P, Peveling⁃Oberhag A, Lang BM, et al. Severe chronic spontaneous urticaria in children ⁃ treatment options according to the guidelines and beyond ⁃ a 10 years review[J]. J Dermatolog Treat, 2020:1⁃4. doi: 10.1080/09546634.2020.1782326. |
[33] | Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease⁃matched comparator cohort[J]. J Allergy Clin Immunol, 2020,145(2):528⁃536.e1. doi: 10.1016/j.jaci.2019.05.019. |
[34] | Liao SL, Yu M, Zhao ZT, et al. Case report: omalizumab for chronic spontaneous urticaria in pregnancy[J]. Front Immunol, 2021,12:652973. doi: 10.3389/fimmu.2021.652973. |
[1] | Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358. |
[2] | Zhou Tiantian, Wu Xuege, Yang Huan, Fang Xiao, Jiang Jinqiu, Chen Jingsi, Luo Xiaoyan, Wang Hua. Analysis of the etiology and factors associated with the severity of chronic spontaneous urticaria in children [J]. Chinese Journal of Dermatology, 2024, 57(4): 324-330. |
[3] | Li Yuanjun, Han Yuyang, Zhang Huanzhen, Wang Hui, Shen Nan, Zhang Xinglian. Dupilumab in the treatment of 12 children with chronic spontaneous urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(3): 254-257. |
[4] | Enze LI Lu CHEN Chu-Qiao ZHANG Jiao qingqing JI Jiang. Correlations of gut microbiota and short-chain fatty acids with chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230310-e20230310. |
[5] | Xu Xili, Li Dongning, Duan Han, Wang Fei. Analysis of plasma amino acid profiles in adolescents and adults with atopic dermatitis [J]. Chinese Journal of Dermatology, 2023, 56(8): 742-750. |
[6] | Zhou Tong, Geng Songmei. Application of biologic agents in the treatment of bullous pemphigoid [J]. Chinese Journal of Dermatology, 2023, 56(8): 789-793. |
[7] | Chen Qiquan, Yang Xianjie, Wang Wenwen, Liang Gaopeng, Song Zhiqiang . Development and application of clinical assessment tools for cholinergic urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 563-566. |
[8] | Jiao Qingqing, Zhang Xiaoyan, Ji Jiang. Biological indicators related to disease activity of chronic spontaneous urticaria: an update [J]. Chinese Journal of Dermatology, 2023, 56(6): 559-562. |
[9] | Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558. |
[10] | Zhang Liming, Xiao Ting. Update of the autoimmune pathogenesis of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 567-570. |
[11] | Yang Nali, Xu Qiuyang, Wu Hanwen, Ye Yahui, Zhu Jiling, Liu Jingjing, Li Zhiming. Efficacy and safety of omalizumab in the treatment of chronic urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 518-524. |
[12] | Chen Qiquan, Kong Minmin, Yang Xianjie, Wang Huan, Li Jian, Zhang Mingwang, Song Zhiqiang. Clinical analysis of allergen reactivity and atopic disease history in 168 patients with chronic inducible urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 496-503. |
[13] | Su Chang, Sui Xiuli, Liu Ruiling, Cao Yiqun, Jiang Hong, Yan Cairong, Wang Huiping, Qi Yuqing. Omalizumab for the treatment of 74 patients with chronic spontaneous urticaria accompanied by other allergic diseases: a clinical analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 512-517. |
[14] | Wang Xin, Liu Lijuan, Li Linfeng. Clinical features of chronic spontaneous urticaria in China: results from a hospital-based multicenter epidemiological survey [J]. Chinese Journal of Dermatology, 2023, 56(6): 525-530. |
[15] | Li Liqiao, Peng Cong, Chen Xiang, Li Jie. Efficacy of omalizumab in the treatment of chronic urticaria patients with poor response to antihistamines: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(6): 504-511. |
|